12 min read
T-Cell Engagers: The Off-the-Shelf Alternative to CAR-T
One arm grabs the cancer cell. The other grabs a T-cell. The bispecific forces them together.
CAR-T cell therapy works but takes weeks to manufacture and costs $400K+ per patient. T-cell engager bispecific antibodies do the same job as an injectable drug - no cell extraction, no manufacturing delay. Ten are now FDA-approved across myeloma, lymphoma, leukemia, and solid tumors, competing directly with CAR-T in the same diseases.